MANE logo

MANE Veradermics, Incorporated

New York Stock Exchange · Biotechnology · Healthcare

$124.39
-0.47 (-0.38%)

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for ch…

Market Cap: $5.25Bwww.veradermics.com

Price

No data yet.

Social Signal Score

41
5d
—
30d
44
4 mentions
—
60d
40
10 mentions
—
90d
40
12 mentions
—
news: 6 · rss: 5 · 4chan: 1

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 0Sell 0Strong Sell 0
Avg price target$174+39.9%
Low $136Median $182High $204
Current Consensus

Revenue

$0.00
$0.00
Dec 2024Sep 2026

Analyst Estimates

FY2025
$-6.75
$-28.48–$-0.54
1 analysts
FY2026
$-2.72
$-11.48–$-0.22
3 analysts
FY2027
$-2.66
$-11.22–$-0.21
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Reid Waldman
Sector
Healthcare
Industry
Biotechnology
Employees
51
Beta
1.23
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
294.66
www.veradermics.com